(Oxford University Press USA) A new study published in the Journal of the National Cancer Institute has identified specific genes associated with increased risk for triple-negative breast cancer, providing the basis for better risk management.

Related Links:

Publication date: Available online 6 August 2018Source: Preventive MedicineAuthor(s): Luz Helena Alba, Sandra Díaz, Oscar Gamboa, César Poveda, Andrés Henao, Fernando Perry, Catherine Duggan, Fabián Gil, Raúl MurilloAbstractMost evidence on breast cancer screening accuracy derives from high income countries. We evaluated screening accuracy and factors related to program implementation in Bogota, Colombia. Between 2008 and 2012 participants underwent clinical breast examination (CBE) and mammography. Positive results underwent histological verification. Adherence to screening protocols was…

Source: Preventive MedicineCategory: International Medicine & Public Health Source Type: research

ConclusionsThe proposed method can be further developed to improve the early diagnosis and diagnostic accuracy and reduce the clinical misdiagnosis rate of breast cancer.Key Points•Microcalcifications are of special importance to indicate early breast cancer.•Grating-based phase-contrast imaging can improve the diagnosis of breast cancers.•The method described here can better classify benign and malignant breast diseases.

Variations among women in breast cancer screening are due to provider and health…Read more on AuntMinnie.comRelated Reading:
Shared decision-making for mammography could be clearer
Radiologist factors influence mammography recall rates
Geographic factors affect mammography uptake
Mammography screening should consider radiation risk
Would risk-based breast screening be more cost-effective?

Conditions:   Metastatic Breast Cancer With HER2 Positive;   Triple Negative Breast Cancer Intervention:   Procedure: Brain MRI Sponsor:   Yonsei University Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Condition:   ER+ HER2- Advanced Breast Cancer Interventions:   Drug: AZD9833;   Drug: AZD9833 with palbociclib Sponsor:   AstraZeneca Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Condition:   Breast Cancer Intervention:   Other: Quality of Life Surveys Sponsor:   The Guthrie Clinic Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Internal mammary chain radiation therapy for breast cancer is associated with increased cardiac toxicity, in particular when paired with anthracyclines.

Source: CancerNetworkCategory: Cancer & Oncology Authors: Source Type: news

We report a case of hypermetabolic internal mammary lymphadenopathy in a breast cancer patient who was previously treated with bilateral mastectomy and implants. The abnormal nodal uptake turned out to be due to foreign body induced inflammation, confirmed on histopathology. Vigilant PET interpretation is required in breast cancer patients with evidence of breast implant rupture.
PMID: 30076249 [PubMed – as supplied by publisher]

Authors: Brito AET, Mourato F, Santos A, Mosci C, Ramos C, Etchebehere E
Abstract
PURPOSE: To validate a semi-automatic quantification of the skeletal tumor burden on 18F-Fluoride PET/CT by using manual quantification as a reference. METHODS: We quantified 51 18F-Fluoride PET/CT exams performed on female breast cancer patients. Clinical information (age, time of disease, presence of visceral metastases, and time to death, progression or bone event) was recorded. The total volume of fluoride-avid skeletal metastases (FTV10) and the total activity of 18F-Fluoride-avid metastases (TLF10) were calculated manually (mTLF…

In this study, we found that miR-1284 was downregulated in breast cancer tissues and cell lines compared to normal control cells. Moreover, we showed that overexpression of miR-1284 significantly inhibited the proliferation, migration and invasion of breast cancer cells while promoting apoptosis. In terms of mechanism, we found that transcription factor ZIC2 was a target of miR-1284 in breast cancer cells. Through luciferase reporter assay, we demonstrated their direct interaction. Besides, qRT-PCR and western blot also indicated that miR-1284 overexpression inhibited the protein levels of ZIC2 in breast cancer cells. More…

Source: Oncology ResearchCategory: Cancer & Oncology Tags: Oncol Res Source Type: research





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image